BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577-1586. [PMID: 27543837 DOI: 10.1002/hep.28785] [Cited by in Crossref: 459] [Cited by in F6Publishing: 452] [Article Influence: 91.8] [Reference Citation Analysis]
Number Citing Articles
1 Trivedi HD, Suri J, Oh D, Schwartz J, Goyes D, Idriss R, Curry MP, Lai M. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Ann Hepatol 2021;24:100336. [PMID: 33647502 DOI: 10.1016/j.aohep.2021.100336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Commun 2019;3:1459-71. [PMID: 31701070 DOI: 10.1002/hep4.1419] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 20.0] [Reference Citation Analysis]
3 Draijer LG, Haggenburg S, Benninga MA, Chegary M, Koot BGP. Survey on screening for paediatric non-alcoholic fatty liver disease in clinical practice in Dutch hospitals. Acta Paediatr 2020;109:2388-93. [PMID: 32271954 DOI: 10.1111/apa.15294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
5 Feldman A, Eder SK, Felder TK, Paulweber B, Zandanell S, Stechemesser L, Schranz M, Strebinger G, Huber-Schönauer U, Niederseer D, Patsch W, Weghuber D, Tevini J, Datz C, Aigner E. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach. Diabetes Metab 2019;45:132-9. [PMID: 30266576 DOI: 10.1016/j.diabet.2018.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gaidos JKJ, Fuchs M. Increased Prevalence of NAFLD in IBD Patients. Dig Dis Sci. 2017;62:1362. [PMID: 28357696 DOI: 10.1007/s10620-017-4552-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30. [DOI: 10.1053/j.gastro.2019.01.042] [Cited by in Crossref: 245] [Cited by in F6Publishing: 211] [Article Influence: 122.5] [Reference Citation Analysis]
8 Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021;73:2028-38. [PMID: 33111374 DOI: 10.1002/hep.31599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
9 Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018;7:F1000 Faculty Rev-720. [PMID: 29946426 DOI: 10.12688/f1000research.14421.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
10 Boland ML, Oldham S, Boland BB, Will S, Lapointe JM, Guionaud S, Rhodes CJ, Trevaskis JL. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol 2018; 24(16): 1748-1765 [PMID: 29713129 DOI: 10.3748/wjg.v24.i16.1748] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
11 Müller MF, Kendall TJ, Adams DJ, Zhou Y, Arends MJ. The murine hepatic sequelae of long-term ethanol consumption are sex-specific and exacerbated by Aldh1b1 loss. Experimental and Molecular Pathology 2018;105:63-70. [DOI: 10.1016/j.yexmp.2018.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Morrison M, Hughes HY, Naggie S, Syn WK. Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? Dig Dis Sci 2019;64:3394-401. [PMID: 31643035 DOI: 10.1007/s10620-019-05861-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ni L, Yu D, Wu T, Jin F. Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: An observational study. Medicine (Baltimore) 2021;100:e24743. [PMID: 33578624 DOI: 10.1097/MD.0000000000024743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi PJ, Tiribelli C, Rosso N. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients 2017;9:E1006. [PMID: 28895929 DOI: 10.3390/nu9091006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
16 Shen SH, Zhong TY, Peng C, Fang J, Lv B. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. BMC Complement Med Ther 2020;20:34. [PMID: 32024509 DOI: 10.1186/s12906-020-2835-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab 2021;50:101143. [PMID: 33346069 DOI: 10.1016/j.molmet.2020.101143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
18 Mukherji A, Bailey SM, Staels B, Baumert TF. The circadian clock and liver function in health and disease. Journal of Hepatology 2019;71:200-11. [DOI: 10.1016/j.jhep.2019.03.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
19 Trifan A, Stanciu C, Jurcău M, Zenovia S, Frunzuc G, Timofte D. Nonalcoholic steatohepatitis: A scientometric analysis of publications during 1980-2018. Medicine (Baltimore) 2019;98:e18221. [PMID: 31852081 DOI: 10.1097/MD.0000000000018221] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chalasani N, Toden S, Sninsky JJ, Rava RP, Braun JV, Gawrieh S, Zhuang J, Nerenberg M, Quake SR, Maddala T. Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. Am J Physiol Gastrointest Liver Physiol 2021;320:G439-49. [PMID: 33501884 DOI: 10.1152/ajpgi.00397.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Yuan T, Wang J, Chen L, Shan J, Di L. Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus. Journal of Functional Foods 2019;52:219-27. [DOI: 10.1016/j.jff.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
22 Álvarez-Amor L, Sierra AL, Cárdenas A, López-Bermudo L, López-Beas J, Andújar E, Pérez-Alegre M, Gallego-Durán R, Varela LM, Martin-Montalvo A, Berná G, Rojas A, Robles-Frías MJ, Hmadcha A, Romero-Gómez M, Kleemann R, Martín F. Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr-/-.Leiden mice without attenuation of steatohepatitis. Sci Rep 2021;11:8250. [PMID: 33859314 DOI: 10.1038/s41598-021-87761-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Antunes MM, Diniz AB, Castro-Oliveira HM, Mendes GAM, Freitas-Lopes MA, de Oliveira Costa KM, Bicalho KM, Nakagaki BNL, Mattos MS, de Miranda CDM, Lopes ME, Melão ACR, Carvalho-Gontijo R, Radhakrishnnan S, Ricci M, Rezende RM, Menezes GB. Chronic ingestion of Primex-Z, compared with other common fat sources, drives worse liver injury and enhanced susceptibility to bacterial infections. Nutrition 2021;81:110938. [PMID: 32739658 DOI: 10.1016/j.nut.2020.110938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Dibba P, Li A, Cholankeril G, Iqbal U, Gadiparthi C, Khan MA, Kim D, Ahmed A. Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. Medicines (Basel) 2018;5:E47. [PMID: 29843404 DOI: 10.3390/medicines5020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68:335-352. [PMID: 29122390 DOI: 10.1016/j.jhep.2017.09.021] [Cited by in Crossref: 224] [Cited by in F6Publishing: 213] [Article Influence: 56.0] [Reference Citation Analysis]
26 Kabiri M, Sexton Ward A, Ramasamy A, van Eijndhoven E, Ganguly R, Smolarz BG, Zvenyach T, Goldman DP, Baumgardner JR. The Societal Value of Broader Access to Antiobesity Medications. Obesity (Silver Spring) 2020;28:429-36. [PMID: 31869002 DOI: 10.1002/oby.22696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Huang HM, Fan SJ, Zhou XR, Liu YJ, Li X, Liao LP, Huang J, Shi CC, Yu L, Fu R, Fan JG, Zhang YY, Luo C, Li GM. Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacol Sin 2021. [PMID: 34341511 DOI: 10.1038/s41401-021-00725-1] [Reference Citation Analysis]
28 Oates JR, McKell MC, Moreno-Fernandez ME, Damen MSMA, Deepe GS Jr, Qualls JE, Divanovic S. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack. Front Immunol 2019;10:2893. [PMID: 31921154 DOI: 10.3389/fimmu.2019.02893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
29 An JP, Dang LH, Ha TKQ, Pham HTT, Lee BW, Lee CH, Oh WK. Flavone glycosides from Sicyos angulatus and their inhibitory effects on hepatic lipid accumulation. Phytochemistry 2019;157:53-63. [PMID: 30368219 DOI: 10.1016/j.phytochem.2018.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Abdallah LR, de Matos RC, e Souza YPDM, Vieira-soares D, Muller-machado G, Pollo-flores P. Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis. Curr Atheroscler Rep 2020;22. [DOI: 10.1007/s11883-020-0820-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
31 Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, Long MT. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol 2019; 17: 1157-1164. e4. [PMID: 30476583 DOI: 10.1016/j.cgh.2018.11.037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
32 Darvish Damavandi R, Shidfar F, Najafi M, Janani L, Masoodi M, Akbari-Fakhrabadi M, Dehnad A. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. Phytother Res 2021;35:3145-56. [PMID: 33880813 DOI: 10.1002/ptr.6972] [Reference Citation Analysis]
33 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
34 Huang XJ, He CJ, Liang S, Wang J, Li J, Yang GZ, Zhao Z. Veratrilla baillonii Franch Could Alleviate Lipid Accumulation in LO2 Cells by Regulating Oxidative, Inflammatory, and Lipid Metabolic Signaling Pathways. Front Pharmacol 2020;11:575772. [PMID: 33071788 DOI: 10.3389/fphar.2020.575772] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
36 Baki JA, Tapper EB. Contemporary Epidemiology of Cirrhosis. Curr Treat Options Gastroenterol 2019;17:244-53. [PMID: 30949926 DOI: 10.1007/s11938-019-00228-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
37 Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML, Marchesini G. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:1014-22. [DOI: 10.1016/j.numecd.2020.02.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
38 Ding H, Huang JF, Xie HS, Wang BY, Lin T, Zhao JM, Lin QC. The association between glycometabolism and nonalcoholic fatty liver disease in patients with obstructive sleep apnea. Sleep Breath 2019;23:373-8. [PMID: 30349997 DOI: 10.1007/s11325-018-1744-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Abdelmalek MF. The clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol 2016;13:685-6. [DOI: 10.1038/nrgastro.2016.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
41 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1354] [Article Influence: 355.3] [Reference Citation Analysis]
42 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
44 Mesnage R, Biserni M, Balu S, Frainay C, Poupin N, Jourdan F, Wozniak E, Xenakis T, Mein CA, Antoniou MN. Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126. Arch Toxicol 2018;92:2533-47. [PMID: 29947894 DOI: 10.1007/s00204-018-2235-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
45 Deng Y, Pan M, Nie H, Zheng C, Tang K, Zhang Y, Yang Q. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Molecules 2019;24:E3943. [PMID: 31683679 DOI: 10.3390/molecules24213943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
47 Al-Qarni R, Iqbal M, Al-Otaibi M, Al-Saif F, Alfadda AA, Alkhalidi H, Bamehriz F, Hassanain M. Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine (Baltimore) 2020;99:e21463. [PMID: 32898995 DOI: 10.1097/MD.0000000000021463] [Reference Citation Analysis]
48 Younossi ZM, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D, Younoszai Z, Jeffers T, Felix S, Jeiran K, Hodge A, Zhou W, Monge F, Alaparthi L, Chandhoke V, Goodman ZD, Petricoin EF. An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. BMC Med 2018;16:170. [PMID: 30205811 DOI: 10.1186/s12916-018-1136-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. Hepatology 2019;69:564-72. [PMID: 30180285 DOI: 10.1002/hep.30254] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 25.0] [Reference Citation Analysis]
50 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
51 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
52 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
54 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 226.0] [Reference Citation Analysis]
55 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
56 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
57 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
58 Suzuki R, Brown GA, Christopher JA, Scully CCG, Congreve M. Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. J Med Chem 2020;63:905-27. [PMID: 31577440 DOI: 10.1021/acs.jmedchem.9b00835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
59 Pickhardt PJ, Graffy PM, Reeder SB, Hernando D, Li K. Quantification of Liver Fat Content With Unenhanced MDCT: Phantom and Clinical Correlation With MRI Proton Density Fat Fraction. AJR Am J Roentgenol 2018;211:W151-7. [PMID: 30016142 DOI: 10.2214/AJR.17.19391] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 10.3] [Reference Citation Analysis]
60 Afonso MB, Rodrigues PM, Mateus-Pinheiro M, Simão AL, Gaspar MM, Majdi A, Arretxe E, Alonso C, Santos-Laso A, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales JM, Ratziu V, Gautheron J, Castro RE, Rodrigues CMP. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut 2021;70:2359-72. [PMID: 33361348 DOI: 10.1136/gutjnl-2020-321767] [Reference Citation Analysis]
61 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Alkhouri N, Gawrieh S. A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opin Investig Drugs 2021;30:237-44. [PMID: 33470860 DOI: 10.1080/13543784.2021.1879792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Gheibi S, Gouvarchin Ghaleh HE, Motlagh BM, Azarbayjani AF, Zarei L. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. Biomed Pharmacother 2019;115:108938. [PMID: 31071511 DOI: 10.1016/j.biopha.2019.108938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
64 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
65 Wu Z, Yang F, Jiang S, Sun X, Xu J. Induction of Liver Steatosis in BAP31-Deficient Mice Burdened with Tunicamycin-Induced Endoplasmic Reticulum Stress. Int J Mol Sci 2018;19:E2291. [PMID: 30081561 DOI: 10.3390/ijms19082291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
66 Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S, Marra F. Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Front Pharmacol 2019;10:604. [PMID: 31191323 DOI: 10.3389/fphar.2019.00604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. Am J Med 2021;134:23-9. [PMID: 32931760 DOI: 10.1016/j.amjmed.2020.08.010] [Reference Citation Analysis]
68 Diniz AB, Antunes MM, Lacerda VAS, Nakagaki BN, Freitas Lopes MA, Castro-Oliveira HM, Mattos MS, Mafra K, de Miranda CDM, de Oliveira Costa KM, Lopes ME, Alvarenga DM, Carvalho-Gontijo R, Marchesi SC, Lacerda DR, de Araújo AM, de Carvalho É, David BA, Santos MM, Lima CX, Silva Gomes JA, Minto Fontes Cal TC, de Souza BR, Couto CA, Faria LC, Teixeira Vidigal PV, Matos Ferreira AV, Radhakrishnnan S, Ricci M, Oliveira AG, Rezende RM, Menezes GB. Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. JHEP Rep 2020;2:100117. [PMID: 32695965 DOI: 10.1016/j.jhepr.2020.100117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
69 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
70 Wang Y, Liang K, Kong W. Intestinal Trefoil Factor 3 Alleviates the Intestinal Barrier Function Through Reducing the Expression of TLR4 in Rats with Nonalcoholic Steatohepatitis. Arch Med Res. 2019;50:2-9. [PMID: 31101239 DOI: 10.1016/j.arcmed.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Shaheen M, Pan D, Schrode KM, Kermah D, Puri V, Zarrinpar A, Elisha D, Najjar SM, Friedman TC. Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. Hepatol Commun 2021. [PMID: 34558824 DOI: 10.1002/hep4.1775] [Reference Citation Analysis]
72 Schulze RJ, Sathyanarayan A, Mashek DG. Breaking fat: The regulation and mechanisms of lipophagy. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:1178-1187. [PMID: 28642194 DOI: 10.1016/j.bbalip.2017.06.008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 23.0] [Reference Citation Analysis]
73 Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306-321. [PMID: 28317925 DOI: 10.1038/nri.2017.11] [Cited by in Crossref: 442] [Cited by in F6Publishing: 431] [Article Influence: 110.5] [Reference Citation Analysis]
74 Shetty A, Syn W. Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2019;35:168-76. [DOI: 10.1097/mog.0000000000000528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
75 Li W, Dorans KS, Wilker EH, Rice MB, Long MT, Schwartz J, Coull BA, Koutrakis P, Gold DR, Fox CS, Mittleman MA. Residential Proximity to Major Roadways, Fine Particulate Matter, and Hepatic Steatosis: The Framingham Heart Study. Am J Epidemiol 2017;186:857-65. [PMID: 28605427 DOI: 10.1093/aje/kwx127] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
76 Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:1608-1619.e13. [PMID: 33307033 DOI: 10.1053/j.gastro.2020.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Patel YA, Gifford EJ, Glass LM, Turner MJ, Han B, Moylan CA, Choi S, Suzuki A, Provenzale D, Hunt CM. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Dig Dis Sci 2018;63:2259-66. [DOI: 10.1007/s10620-018-5123-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
78 Canbay A, Kachru N, Haas JS, Meise D, Ozbay AB, Sowa JP. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med 2021;9:615. [PMID: 33987313 DOI: 10.21037/atm-20-7179] [Reference Citation Analysis]
79 Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol Commun 2020;4:478-92. [PMID: 32258944 DOI: 10.1002/hep4.1479] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 50.0] [Reference Citation Analysis]
80 Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
81 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
82 Younossi ZM, Henry L, Bush H, Mishra A. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:1-10. [PMID: 29128049 DOI: 10.1016/j.cld.2017.08.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
83 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Reference Citation Analysis]
85 Manley K, Bravo-Nuevo A, Minton AR, Sedano S, Marcy A, Reichman M, Tobia A, Artlett CM, Gilmour SK, Laury-Kleintop LD, Prendergast GC. Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine. J Cell Biochem 2019. [PMID: 30809852 DOI: 10.1002/jcb.28492] [Reference Citation Analysis]
86 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
87 Li H, Hu Y. Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease. Chin J Integr Med 2020;26:723-8. [DOI: 10.1007/s11655-020-3268-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
88 Chan DFY, So HK, Hui SCN, Chan RSM, Li AM, Sea MM, Chu WCW, Chan M, Woo J, Nelson EAS. Dietitian-led lifestyle modification programme for obese Chinese adolescents with non-alcoholic fatty liver disease: a randomized controlled study. Int J Obes (Lond) 2018;42:1680-90. [PMID: 29453464 DOI: 10.1038/s41366-018-0010-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
89 Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018;6:264-275. [PMID: 30271738 DOI: 10.14218/jcth.2017.00056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
90 Koutoukidis DA, Morris E, Henry JA, Shammoon Y, Zimmerman M, Michalopoulou M, Jebb SA, Aveyard P. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLoS One 2021;16:e0250385. [PMID: 33882107 DOI: 10.1371/journal.pone.0250385] [Reference Citation Analysis]
91 Shaheen AA, Nguyen HH, Congly SE, Kaplan GG, Swain MG. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39:878-884. [PMID: 30688401 DOI: 10.1111/liv.14054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
92 Hagström H, Nasr P, Ekstedt M, Hammar U, Widman L, Stål P, Hultcrantz R, Kechagias S, Henriksson M. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clinical Gastroenterology and Hepatology 2020;18:1592-1599.e8. [DOI: 10.1016/j.cgh.2019.10.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
93 Unger LW, Forstner B, Muckenhuber M, Scheuba K, Eigenbauer E, Scheiner B, Pfisterer N, Paternostro R, Trauner M, Mandorfer M, Reiberger T. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Dig Dis Sci. 2020;65:2712-2718. [PMID: 31875288 DOI: 10.1007/s10620-019-06000-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Han Y, Zhang Y, Liu S, Chen G, Cao L, Xin Y. Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. J Clin Transl Hepatol 2021;9:203-9. [PMID: 34007802 DOI: 10.14218/JCTH.2020.00163] [Reference Citation Analysis]
95 Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic Liver Disease Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. Am J Gastroenterol 2020;115:96-104. [DOI: 10.14309/ajg.0000000000000380] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
96 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 57.3] [Reference Citation Analysis]
97 Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00567-X. [PMID: 34033923 DOI: 10.1016/j.cgh.2021.05.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Gunn PJ, Green CJ, Pramfalk C, Hodson L. In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum. Physiol Rep 2017;5:e13532. [PMID: 29263118 DOI: 10.14814/phy2.13532] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
99 Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, Lee KM, Shin SJ, Lee KJ, Kim JH, Cheong JY, Cho SW, Kim SS. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut Liver 2019;13:440-9. [PMID: 30970431 DOI: 10.5009/gnl18382] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
100 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
101 Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69:1155-1163. [PMID: 30290973 DOI: 10.1016/j.jhep.2018.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
102 Kim BM, Abdelfattah AM, Vasan R, Fuchs BC, Choi MY. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Sci Rep 2018;8:7499. [PMID: 29760499 DOI: 10.1038/s41598-018-25699-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
103 Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol 2020;18:216-225.e5. [PMID: 31195161 DOI: 10.1016/j.cgh.2019.05.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
104 Matsumoto M, Yashiro H, Ogino H, Aoyama K, Nambu T, Nakamura S, Nishida M, Wang X, Erion DM, Kaneko M. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS One 2020;15:e0228212. [PMID: 31990961 DOI: 10.1371/journal.pone.0228212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Nakashita C, Xi L, Inoue Y, Kabura R, Masuda S, Yamano Y, Katoh T. Impact of dietary compositions and patterns on the prevalence of nonalcoholic fatty liver disease in Japanese men: a cross-sectional study. BMC Gastroenterol 2021;21:342. [PMID: 34481454 DOI: 10.1186/s12876-021-01919-x] [Reference Citation Analysis]
106 Mouzaki M, Trout AT. Virtual Reality: New Insights Regarding the Prevalence of Nonalcoholic Fatty Liver Disease in Children and Adolescents with Obesity Using Magnetic Resonance Imaging. The Journal of Pediatrics 2019;207:8-10. [DOI: 10.1016/j.jpeds.2018.12.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Geier A, Eichinger M, Stirnimann G, Semela D, Tay F, Seifert B, Tschopp O, Bantel H, Jahn D, Marques Maggio E, Saleh L, Bischoff-Ferrari HA, Müllhaupt B, Dufour JF. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scand J Gastroenterol 2018;53:1114-20. [PMID: 30270688 DOI: 10.1080/00365521.2018.1501091] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
109 Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, Tudor K, Bodenham E, Dunnigan A, Jebb SA, Aveyard P. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021;115:154455. [PMID: 33259835 DOI: 10.1016/j.metabol.2020.154455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
110 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 719] [Article Influence: 345.0] [Reference Citation Analysis]
111 Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig Liver Dis 2019;51:462-70. [PMID: 30733187 DOI: 10.1016/j.dld.2018.12.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
112 Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Navas Jimenez C, Sakka M, Bouam S, Retbi A, Krasteva D, Meritet JF, Schwarzinger M, Thabut D, Rufat P, Bonnefont-Rousselot D, Sogni P, Pol S, Tsochatzis E; Demosthenes research group. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol 2021:S0168-8278(21)02092-4. [PMID: 34606913 DOI: 10.1016/j.jhep.2021.09.030] [Reference Citation Analysis]
113 Xia Y, Wu Q, Dai H, Lv J, Liu Y, Sun H, Jiang Y, Chang Q, Niu K, Zhao Y. Associations of Nutritional, Lifestyle, and Metabolic Factors With Non-alcoholic Fatty Liver Disease: An Umbrella Review With More Than 380,000 Participants. Front Nutr 2021;8:642509. [PMID: 34604270 DOI: 10.3389/fnut.2021.642509] [Reference Citation Analysis]
114 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Arrese M, Feldstein AE. Nash-Related Cirrhosis: An Occult Liver Disease Burden. Hepatol Commun. 2017;1:84-86. [PMID: 29335681 DOI: 10.1002/hep4.1033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
116 Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. Liver Int 2017;37:906-18. [DOI: 10.1111/liv.13329] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
117 Smeuninx B, Boslem E, Febbraio MA. Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2020;12:E1714. [PMID: 32605253 DOI: 10.3390/cancers12071714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
118 Younossi ZM, Tampi RP, Nader F, Younossi IM, Cable R, Srishord M, Racila A. Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. Liver Int 2020;40:308-18. [PMID: 31705834 DOI: 10.1111/liv.14292] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
119 Hernandez GV, Smith VA, Melnyk M, Burd MA, Sprayberry KA, Edwards MS, Peterson DG, Bennet DC, Fanter RK, Columbus DA, Steibel JP, Glanz H, Immoos C, Rice MS, Santiago-Rodriguez TM, Blank J, VanderKelen JJ, Kitts CL, Piccolo BD, La Frano MR, Burrin DG, Maj M, Manjarin R. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastrointest Liver Physiol 2020;318:G582-609. [PMID: 32003601 DOI: 10.1152/ajpgi.00344.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
120 Cabré N, Camps J, Joven J. Inflammation, mitochondrial metabolism and nutrition: the multi-faceted progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:438-43. [PMID: 27826560 DOI: 10.21037/hbsn.2016.09.11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
121 Lebeaupin C, Vallée D, Rousseau D, Patouraux S, Bonnafous S, Adam G, Luciano F, Luci C, Anty R, Iannelli A, Marchetti S, Kroemer G, Lacas-Gervais S, Tran A, Gual P, Bailly-Maitre B. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. Hepatology 2018;68:515-32. [PMID: 29457838 DOI: 10.1002/hep.29847] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
122 Mindikoglu AL, Opekun AR, Gagan SK, Devaraj S. Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2017;2017:3932491. [PMID: 29348746 DOI: 10.1155/2017/3932491] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
123 Chen Z, Cao Y, Zhang Y, Qiao Y. A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. Int J Mol Sci 2019;20:E752. [PMID: 30754631 DOI: 10.3390/ijms20030752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
124 Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol 2019;15:e8793. [PMID: 30824564 DOI: 10.15252/msb.20188793] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 35.0] [Reference Citation Analysis]
125 Francque S, Vonghia L. The future of diagnosing NASH - could a simple blood test be the key? Expert Rev Gastroenterol Hepatol 2017;11:995-7. [PMID: 28862886 DOI: 10.1080/17474124.2017.1374851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
126 Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672-2682. [PMID: 30179269 DOI: 10.1002/hep.30251] [Cited by in Crossref: 351] [Cited by in F6Publishing: 353] [Article Influence: 351.0] [Reference Citation Analysis]
127 Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, Yu J, Teoh NC, Farrell GC. Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature: Systematic review of mouse NASH models. Journal of Gastroenterology and Hepatology 2018;33:1312-20. [DOI: 10.1111/jgh.14122] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
128 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
129 Bulutoglu B, Rey-Bedón C, Kang YBA, Mert S, Yarmush ML, Usta OB. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation. Lab Chip 2019;19:3022-31. [PMID: 31465069 DOI: 10.1039/c9lc00354a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
130 Li H, Xi Y, Xin X, Tian H, Hu Y. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. Biomed Pharmacother 2020;124:109915. [PMID: 31986416 DOI: 10.1016/j.biopha.2020.109915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
131 Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. Biochim Biophys Acta Mol Basis Dis 2019;1865:943-53. [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
132 Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials 2020;88:105889. [DOI: 10.1016/j.cct.2019.105889] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
133 Zhou YJ, Zhou YF, Zheng JN, Liu WY, Van Poucke S, Zou TT, Zhang DC, Shen S, Shi KQ, Wang XD, Zheng MH. NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. Clin Chim Acta. 2017;475:44-50. [PMID: 28964832 DOI: 10.1016/j.cca.2017.09.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
134 Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? World J Gastroenterol 2021; 27(35): 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803] [Reference Citation Analysis]
135 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01055-7. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Reference Citation Analysis]
136 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
137 Lauschke VM, Shafagh RZ, Hendriks DFG, Ingelman-Sundberg M. 3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. Biotechnol J 2019;14:e1800347. [PMID: 30957976 DOI: 10.1002/biot.201800347] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 22.0] [Reference Citation Analysis]
138 Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY. Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clin Pharmacol Drug Dev 2021;10:68-77. [PMID: 32191400 DOI: 10.1002/cpdd.790] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Mardinoglu A, Ural D, Zeybel M, Yuksel HH, Uhlén M, Borén J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 2019;11:E1578. [PMID: 31336926 DOI: 10.3390/nu11071578] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
141 Yip TC, Ma AJ, Wong VW, Tse Y, Chan HL, Yuen P, Wong GL. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther 2017;46:447-56. [DOI: 10.1111/apt.14172] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
142 Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019;48:281-289. [PMID: 31046975 DOI: 10.1016/j.gtc.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
143 Younossi ZM. Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. Hepatology 2018;68:2405-12. [PMID: 30070714 DOI: 10.1002/hep.30125] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
144 Lv G, Cheng N, Wang H. The Gut Microbiota, Tumorigenesis, and Liver Diseases. Engineering 2017;3:110-4. [DOI: 10.1016/j.eng.2017.01.017] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
145 de Franchis R, Krag A. Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy? Journal of Hepatology 2018;69:769-71. [DOI: 10.1016/j.jhep.2018.06.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
146 Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
147 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
148 Cordoba-Chacon J, Sarmento-Cabral A, Del Rio-Moreno M, Diaz-Ruiz A, Subbaiah PV, Kineman RD. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction. Endocrinology 2018;159:3761-74. [PMID: 30295789 DOI: 10.1210/en.2018-00669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
149 dos Santos Carvalho J, Cardoso Guimarães Vasconcelos AC, Herlany Pereira Alves E, dos Santos Carvalho A, da Silva FRP, de Carvalho França LF, de Pádua Rocha Nóbrega Neto A, Di Lenardo D, de Souza LKM, Barbosa ALDR, Medeiros JR, de Oliveira JS, Vasconcelos DFP. Steatosis caused by experimental periodontitis is reversible after removal of ligature in rats. J Periodont Res 2017;52:883-92. [DOI: 10.1111/jre.12459] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
150 Wang Q, Xie W, Liu L, Wang P, Pan CQ. Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e25327. [PMID: 33950921 DOI: 10.1097/MD.0000000000025327] [Reference Citation Analysis]
151 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
152 Ramai D, Tai W, Rivera M, Facciorusso A, Tartaglia N, Pacilli M, Ambrosi A, Cotsoglou C, Sacco R. Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. Biomedicines 2021;9:184. [PMID: 33673113 DOI: 10.3390/biomedicines9020184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
154 Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia 2018;61:2235-46. [PMID: 30032428 DOI: 10.1007/s00125-018-4685-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
155 Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME; NASHNET. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.Gastroenterology. 2020;159:1985-1987.e4. [PMID: 32763241 DOI: 10.1053/j.gastro.2020.07.050] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
156 Lam B, Kurzke K, Younossi Z. The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Curr Hepatology Rep 2018;17:345-9. [DOI: 10.1007/s11901-018-0423-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
158 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
159 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
160 Zhou H, Du W, Li Y, Shi C, Hu N, Ma S, Wang W, Ren J. Effects of melatonin on fatty liver disease: The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy. J Pineal Res 2018;64. [PMID: 28981157 DOI: 10.1111/jpi.12450] [Cited by in Crossref: 140] [Cited by in F6Publishing: 142] [Article Influence: 35.0] [Reference Citation Analysis]
161 Cimini FA, Barchetta I, Carotti S, Morini S, Cavallo MG. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. World J Gastrointest Pathophysiol 2019; 10(2): 11-16 [PMID: 31559105 DOI: 10.4291/wjgp.v10.i2.11] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
162 Singh A, Gosai F, Siddiqui MT, Gupta M, Lopez R, Lawitz E, Poordad F, Carey W, McCullough A, Alkhouri N. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2020;54:891-7. [PMID: 32168133 DOI: 10.1097/MCG.0000000000001339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
163 Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm Bowel Dis 2021:izab199. [PMID: 34374782 DOI: 10.1093/ibd/izab199] [Reference Citation Analysis]
164 Zhang L, Yang SY, Qi-Li FR, Liu XX, Zhang WT, Peng C, Wu P, Li P, Li P, Xu X. Administration of isoliquiritigenin prevents nonalcoholic fatty liver disease through a novel IQGAP2-CREB-SIRT1 axis. Phytother Res 2021;35:3898-915. [PMID: 33860590 DOI: 10.1002/ptr.7101] [Reference Citation Analysis]
165 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
166 Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. PLoS One 2021;16:e0251741. [PMID: 34019560 DOI: 10.1371/journal.pone.0251741] [Reference Citation Analysis]
167 Verhoeven F, Weil-Verhoeven D, Prati C, Martino VD, Thevenot T, Wendling D. Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. Semin Arthritis Rheum 2020;50:544-8. [PMID: 32446022 DOI: 10.1016/j.semarthrit.2020.03.013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
168 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Funuyet-Salas J, Pérez-San-Gregorio MÁ, Martín-Rodríguez A, Romero-Gómez M. Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2020;7:585425. [PMID: 33195340 DOI: 10.3389/fmed.2020.585425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
170 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 594] [Cited by in F6Publishing: 570] [Article Influence: 148.5] [Reference Citation Analysis]
171 Rosso N, Stephenson AM, Giraudi PJ, Tiribelli C. Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. Ann Transl Med 2021;9:727. [PMID: 33987425 DOI: 10.21037/atm-20-4723] [Reference Citation Analysis]
172 Langford CR, Goldinger MH, Treanor D, McGenity C, Dillman JR, Allende DS, Goldin R, Brunt EM, Zatloukal K, Denk H, Fleming KA. Improved pathology reporting in NAFLD/NASH for clinical trials. J Clin Pathol 2021:jclinpath-2021-207967. [PMID: 34753791 DOI: 10.1136/jclinpath-2021-207967] [Reference Citation Analysis]
173 A Abdel Jaleel G, A Al-Awdan S, F Ahmed R, A H Ahmed-Farid O, Saleh DO. Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study. Metab Brain Dis 2020;35:1251-61. [PMID: 32696189 DOI: 10.1007/s11011-020-00593-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Rubino F, Cohen RV, Mingrone G, le Roux CW, Mechanick JI, Arterburn DE, Vidal J, Alberti G, Amiel SA, Batterham RL, Bornstein S, Chamseddine G, Del Prato S, Dixon JB, Eckel RH, Hopkins D, McGowan BM, Pan A, Patel A, Pattou F, Schauer PR, Zimmet PZ, Cummings DE. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol 2020;8:640-8. [PMID: 32386567 DOI: 10.1016/S2213-8587(20)30157-1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 29] [Article Influence: 76.0] [Reference Citation Analysis]
175 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
176 Yin Z, Murphy MC, Li J, Glaser KJ, Mauer AS, Mounajjed T, Therneau TM, Liu H, Malhi H, Manduca A, Ehman RL, Yin M. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. Eur Radiol 2019;29:5823-31. [PMID: 30887196 DOI: 10.1007/s00330-019-06076-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
177 Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther 2021;43:473-99. [PMID: 33526312 DOI: 10.1016/j.clinthera.2021.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
178 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
179 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
180 Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, Bruni CM, Ouyang Z, Li RZ, Sun X, Vu BT, Pasillas MP, Ego KM, Gosselin D, Link VM, Chong LW, Evans RM, Thompson BM, McDonald JG, Hosseini M, Witztum JL, Germain RN, Glass CK. Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. Immunity 2020;52:1057-1074.e7. [PMID: 32362324 DOI: 10.1016/j.immuni.2020.04.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 59.0] [Reference Citation Analysis]
181 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38 Suppl 1:2-6. [PMID: 29427496 DOI: 10.1111/liv.13682] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 80.5] [Reference Citation Analysis]
183 Schild MH, Guy CD. Nonalcoholic Steatohepatitis. Surgical Pathology Clinics 2018;11:267-85. [DOI: 10.1016/j.path.2018.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
184 Paik JM, Henry L, Golabi P, Alqahtani SA, Trimble G, Younossi ZM. Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016. Open Forum Infect Dis 2020;7:ofz509. [PMID: 31921938 DOI: 10.1093/ofid/ofz509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
185 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Povsic M, Oliver L, Jiandani NR, Perry R, Bottomley J. A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). Pharmacol Res Perspect 2019;7:e00485. [PMID: 31149341 DOI: 10.1002/prp2.485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
187 Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-Induced Fatty Liver Disease. Diabetes Metab Syndr Obes 2020;13:1133-45. [PMID: 32368109 DOI: 10.2147/DMSO.S247379] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
188 Yamashima M, Miyaaki H, Miuma S, Shibata H, Sasaki R, Haraguchi M, Fukushima M, Nakao K. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease. Intern Med 2019;58:1987-92. [PMID: 31308341 DOI: 10.2169/internalmedicine.2566-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
189 Goh GB, Leow WQ, Liang S, Wan WK, Lim TKH, Tan CK, Chang PE. Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence. Sci Rep 2019;9:2975. [PMID: 30814650 DOI: 10.1038/s41598-019-39783-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
190 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 34.3] [Reference Citation Analysis]
191 Orkin S, Yodoshi T, Sun Q, Fei L, Meryum S, Arce-Clachar AC, Bramlage K, Beck AF, Mouzaki M. Can Baseline Characteristics be Used to Predict Liver Disease Outcomes in Pediatric Nonalcoholic Fatty Liver Disease? Obesity (Silver Spring) 2021;29:171-6. [PMID: 33185977 DOI: 10.1002/oby.22999] [Reference Citation Analysis]
192 Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155:1463-1473.e6. [PMID: 30059671 DOI: 10.1053/j.gastro.2018.07.027] [Cited by in Crossref: 111] [Cited by in F6Publishing: 117] [Article Influence: 37.0] [Reference Citation Analysis]
193 Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. PLoS One. 2019;14:e0213692. [PMID: 30870486 DOI: 10.1371/journal.pone.0213692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
194 DiStefano JK, Shaibi GQ. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes. 2020;e12759. [PMID: 33305889 DOI: 10.1111/ijpo.12759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
195 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
196 Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, Mchutchison JG, Goodman Z. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int 2018;38:1849-59. [DOI: 10.1111/liv.13706] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
197 Rustgi VK, Li Y, John T, Catalano C, Elsaid MI. Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real-World Claims Analysis. Hepatol Commun. 2020;4:1404-1418. [PMID: 33024912 DOI: 10.1002/hep4.1573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
198 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 23.7] [Reference Citation Analysis]
199 Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis 2018;17:262. [PMID: 30458848 DOI: 10.1186/s12944-018-0913-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
200 Cook NS, Nagar SH, Jain A, Balp MM, Mayländer M, Weiss O, Chatterjee S. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study. Adv Ther 2019;36:478-91. [PMID: 30547371 DOI: 10.1007/s12325-018-0856-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
201 Remmerie A, Scott CL. Macrophages and lipid metabolism. Cell Immunol 2018;330:27-42. [PMID: 29429624 DOI: 10.1016/j.cellimm.2018.01.020] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 41.0] [Reference Citation Analysis]
202 Abeles RD, Mullish BH, Forlano R, Kimhofer T, Adler M, Tzallas A, Giannakeas N, Yee M, Mayet J, Goldin RD, Thursz MR, Manousou P. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther. 2019;49:1077-1085. [PMID: 30836450 DOI: 10.1111/apt.15192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
203 Vreman RA, Goodell AJ, Rodriguez LA, Porco TC, Lustig RH, Kahn JG. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open 2017;7:e013543. [PMID: 28775179 DOI: 10.1136/bmjopen-2016-013543] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
204 Funuyet-salas J, Martín-rodríguez A, Conrad R, Pérez-san-gregorio MÁ. Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis. In: Romero-gomez M, editor. NAFLD and NASH. Cham: Springer International Publishing; 2020. pp. 205-23. [DOI: 10.1007/978-3-030-37173-9_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
205 Geier A, Rau M. Emerging therapies for NASH - the future is now. Expert Rev Clin Pharmacol 2017;10:467-9. [PMID: 28277800 DOI: 10.1080/17512433.2017.1305269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
206 Östlund C, Hernandez-Ono A, Shin JY. The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD. Biology (Basel) 2020;9:E338. [PMID: 33076344 DOI: 10.3390/biology9100338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Beck JR, Cabral F, Rasineni K, Casey CA, Harris EN, Stains CI. A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease. Biochemistry 2019;58:3911-7. [PMID: 31433166 DOI: 10.1021/acs.biochem.9b00547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Petroff D, Blüher M, Wiegand J. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society. Dig Liver Dis 2018;50:731-3. [PMID: 29699861 DOI: 10.1016/j.dld.2018.03.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
210 Jepsen P, Younossi ZM. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. J Hepatol 2021;75 Suppl 1:S3-S13. [PMID: 34039490 DOI: 10.1016/j.jhep.2020.11.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
212 Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 2019;60:1270-83. [PMID: 31113816 DOI: 10.1194/jlr.M093229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
213 Balp MM, Krieger N, Przybysz R, Way N, Cai J, Zappe D, McKenna SJ, Wall G, Janssens N, Tapper E. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. JHEP Rep 2019;1:154-61. [PMID: 32039365 DOI: 10.1016/j.jhepr.2019.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
214 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 46.0] [Reference Citation Analysis]
215 Silva JCP, Mota M, Martins FO, Nogueira C, Gonçalves T, Carneiro T, Pinto J, Duarte D, Barros AS, Jones JG, Gil AM. Intestinal Microbial and Metabolic Profiling of Mice Fed with High-Glucose and High-Fructose Diets. J Proteome Res 2018;17:2880-91. [PMID: 29923728 DOI: 10.1021/acs.jproteome.8b00354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
216 Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, Zhao Y, He Y. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:43. [PMID: 33509116 DOI: 10.1186/s12876-021-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Serfaty L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int 2018;38 Suppl 1:52-5. [PMID: 29427486 DOI: 10.1111/liv.13637] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
218 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 758] [Article Influence: 259.0] [Reference Citation Analysis]
219 Legler J, Zalko D, Jourdan F, Jacobs M, Fromenty B, Balaguer P, Bourguet W, Munic Kos V, Nadal A, Beausoleil C, Cristobal S, Remy S, Ermler S, Margiotta-Casaluci L, Griffin JL, Blumberg B, Chesné C, Hoffmann S, Andersson PL, Kamstra JH. The GOLIATH Project: Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds. Int J Mol Sci 2020;21:E3480. [PMID: 32423144 DOI: 10.3390/ijms21103480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
220 Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Dig Liver Dis 2021;53:598-605. [PMID: 33172809 DOI: 10.1016/j.dld.2020.10.025] [Reference Citation Analysis]
221 Saeed N, Glass LM, Habbal H, Mahmood A, Sengstock D, Saini SD, Tincopa MA. Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. Therap Adv Gastroenterol 2021;14:17562848211042200. [PMID: 34567270 DOI: 10.1177/17562848211042200] [Reference Citation Analysis]
222 Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-1891. [PMID: 28774887 DOI: 10.1136/gutjnl-2017-314307] [Cited by in Crossref: 166] [Cited by in F6Publishing: 172] [Article Influence: 41.5] [Reference Citation Analysis]
223 Nguyen TN, Podkowa AS, Tam AY, Arnold EC, Miller RJ, Park TH, Do MN, Oelze ML. Characterizing Fatty Liver in vivo in Rabbits, Using Quantitative Ultrasound. Ultrasound Med Biol 2019;45:2049-62. [PMID: 31076231 DOI: 10.1016/j.ultrasmedbio.2019.03.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
224 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
225 Dismuke-Greer CE, Syn WK. Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth. Dig Dis Sci 2019;64:606-8. [PMID: 30560337 DOI: 10.1007/s10620-018-5426-4] [Reference Citation Analysis]
226 Schulze RJ, Schott MB, Casey CA, Tuma PL, McNiven MA. The cell biology of the hepatocyte: A membrane trafficking machine. J Cell Biol 2019;218:2096-112. [PMID: 31201265 DOI: 10.1083/jcb.201903090] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
227 Etminani R, Manaf ZA, Shahar S, Azadbakht L, Adibi P. Predictors of Nonalcoholic Fatty Liver Disease Among Middle-Aged Iranians. Int J Prev Med 2020;11:113. [PMID: 33088441 DOI: 10.4103/ijpvm.IJPVM_274_19] [Reference Citation Analysis]
228 Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240-7. [PMID: 34486981 DOI: 10.1530/EC-21-0048] [Reference Citation Analysis]
229 Zhang G, Wang X, Chung TY, Ye W, Hodge L, Zhang L, Chng K, Xiao YF, Wang YJ. Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). BMC Gastroenterol 2020;20:339. [PMID: 33059584 DOI: 10.1186/s12876-020-01467-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Atsawarungruangkit A, Laoveeravat P, Promrat K. Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database. World J Hepatol 2021; 13(10): 1417-1427 [DOI: 10.4254/wjh.v13.i10.1417] [Reference Citation Analysis]
231 Bucher S, Tête A, Podechard N, Liamin M, Le Guillou D, Chevanne M, Coulouarn C, Imran M, Gallais I, Fernier M, Hamdaoui Q, Robin MA, Sergent O, Fromenty B, Lagadic-Gossmann D. Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Sci Rep 2018;8:5963. [PMID: 29654281 DOI: 10.1038/s41598-018-24403-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
232 Wijarnpreecha K, Lou S, Panjawatanan P, Cheungpasitporn W, Pungpapong S, Lukens FJ, Ungprasert P. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis 2018;50:1166-75. [PMID: 30292566 DOI: 10.1016/j.dld.2018.09.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
233 Hou XD, Yan N, Du YM, Liang H, Zhang ZF, Yuan XL. Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. Int J Mol Sci 2020;21:E5375. [PMID: 32751062 DOI: 10.3390/ijms21155375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
234 Liu Z, Suo C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00379-0. [PMID: 34348882 DOI: 10.1016/j.dld.2021.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM; EASL International Liver Foundation NAFLD Policy Review Collaborators. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol 2020;72:14-24. [PMID: 31518646 DOI: 10.1016/j.jhep.2019.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 25.0] [Reference Citation Analysis]
236 Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (Baltimore) 2020;99:e23506. [PMID: 33327291 DOI: 10.1097/MD.0000000000023506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Kwon HC, Kim DH, Jeong CH, Kim YJ, Han JH, Lim SJ, Shin DM, Kim DW, Han SG. Tebuconazole Fungicide Induces Lipid Accumulation and Oxidative Stress in HepG2 Cells. Foods 2021;10:2242. [PMID: 34681291 DOI: 10.3390/foods10102242] [Reference Citation Analysis]
238 Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.Aliment Pharmacol Ther. 2020;52:513-526. [PMID: 32598051 DOI: 10.1111/apt.15830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
239 Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, Hill J, Boustany-Kari CM, Doerner JF, Rippmann JF, Chung RT, Ho Sui SJ, Simon E, Corey KE. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 2021;11:18045. [PMID: 34508113 DOI: 10.1038/s41598-021-96966-5] [Reference Citation Analysis]
240 Durand F, Francoz C. The future of liver transplantation for viral hepatitis. Liver Int 2017;37:130-5. [DOI: 10.1111/liv.13310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
241 Chai C, Cox B, Yaish D, Gross D, Rosenberg N, Amblard F, Shemuelian Z, Gefen M, Korach A, Tirosh O, Lanton T, Link H, Tam J, Permyakova A, Ozhan G, Citrin J, Liao H, Tannous M, Hahn M, Axelrod J, Arretxe E, Alonso C, Martinez-Arranz I, Betés PO, Safadi R, Salhab A, Amer J, Tber Z, Mengshetti S, Giladi H, Schinazi RF, Galun E. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology 2020;159:999-1014.e9. [PMID: 32450149 DOI: 10.1053/j.gastro.2020.05.056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
242 Wijarnpreecha K, Thongprayoon C, Boonpheng B, Panjawatanan P, Sharma K, Ungprasert P, Pungpapong S, Cheungpasitporn W. Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:986-994. [PMID: 29787418 DOI: 10.1097/meg.0000000000001169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
243 Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? World J Hepatol 2021; 13(2): 233-241 [PMID: 33708352 DOI: 10.4254/wjh.v13.i2.233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
244 Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 2017;37:1209-18. [PMID: 28211165 DOI: 10.1111/liv.13391] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
245 Saokaew S, Kanchanasurakit S, Kositamongkol C, Chaiyo K, Jirapisut T, Aomsin N, Leewongsakorn P, Chaiyakunapruk N, Phisalprapa P. Effects of Telemedicine on Obese Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:723790. [PMID: 34490309 DOI: 10.3389/fmed.2021.723790] [Reference Citation Analysis]
246 Rajcic D, Brandt A, Jin CJ, Sánchez V, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance. PLoS One 2020;15:e0237946. [PMID: 32881925 DOI: 10.1371/journal.pone.0237946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Yang J, Sáinz N, Félix-Soriano E, Gil-Iturbe E, Castilla-Madrigal R, Fernández-Galilea M, Martínez JA, Moreno-Aliaga MJ. Effects of Long-Term DHA Supplementation and Physical Exercise on Non-Alcoholic Fatty Liver Development in Obese Aged Female Mice. Nutrients 2021;13:501. [PMID: 33546405 DOI: 10.3390/nu13020501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Narciso-Schiavon JL, Schiavon LL. To screen or not to screen? Celiac antibodies in liver diseases. World J Gastroenterol 2017; 23(5): 776-791 [PMID: 28223722 DOI: 10.3748/wjg.v23.i5.776] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
249 Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol 2018;71:2162-75. [PMID: 29747837 DOI: 10.1016/j.jacc.2018.03.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 29.0] [Reference Citation Analysis]
250 Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci Transl Med 2017;9:eaal3694. [PMID: 28659437 DOI: 10.1126/scitranslmed.aal3694] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]
251 Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. [PMID: 28241825 DOI: 10.1186/s12916-017-0806-8] [Cited by in Crossref: 153] [Cited by in F6Publishing: 138] [Article Influence: 38.3] [Reference Citation Analysis]
252 Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun 2021;5:938-46. [PMID: 34141981 DOI: 10.1002/hep4.1689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 da Silva RP, Eudy BJ, Deminice R. One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All. J Nutr 2020;150:994-1003. [PMID: 32119738 DOI: 10.1093/jn/nxaa032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
254 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01153-8. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Reference Citation Analysis]
255 Mantovani A, Dauriz M, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism 2018;87:1-12. [DOI: 10.1016/j.metabol.2018.06.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
256 Ahn Y, Yun SC, Lee SS, Son JH, Jo S, Byun J, Sung YS, Kim HS, Yu ES. Development and Validation of a Simple Index Based on Non-Enhanced CT and Clinical Factors for Prediction of Non-Alcoholic Fatty Liver Disease. Korean J Radiol 2020;21:413-21. [PMID: 32193889 DOI: 10.3348/kjr.2019.0703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
257 Jamwal R, Barlock BJ. Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals (Basel) 2020;13:E222. [PMID: 32872474 DOI: 10.3390/ph13090222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
258 van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses 2019;122:188-97. [PMID: 30593409 DOI: 10.1016/j.mehy.2018.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
259 Giménez-Garzó C, Fiorillo A, Ballester-Ferré MP, Gallego JJ, Casanova-Ferrer F, Urios A, Benlloch S, Martí-Aguado D, San-Miguel T, Tosca J, Ríos MP, Montón C, Durbán L, Escudero-García D, Aparicio L, Felipo V, Montoliu C. A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. J Clin Med 2021;10:2806. [PMID: 34202269 DOI: 10.3390/jcm10132806] [Reference Citation Analysis]
260 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
261 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
262 Golovaty I, Tien PC, Price JC, Sheira L, Seligman H, Weiser SD. Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. J Nutr 2020;150:91-8. [PMID: 31504710 DOI: 10.1093/jn/nxz212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
263 Chung GE, Kim D, Kwak MS, Yim JY, Ahmed A, Kim JS. Longitudinal Change in Thyroid-Stimulating Hormone and Risk of Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021;19:848-849.e1. [PMID: 32109637 DOI: 10.1016/j.cgh.2020.02.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
265 Parizadeh SM, Parizadeh SA, Alizade-noghani M, Jafarzadeh-esfehani R, Ghandehari M, Mottaghi-moghaddam A, Goldani F, Khazaei M, Ghayour-mobarhan M, Ferns GA, Hassanian SM, Avan A. Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Review of Gastroenterology & Hepatology 2019;13:633-41. [DOI: 10.1080/17474124.2019.1617696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
266 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-376. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 56.8] [Reference Citation Analysis]
267 Della Torre S. Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling. Front Endocrinol (Lausanne) 2020;11:572490. [PMID: 33071979 DOI: 10.3389/fendo.2020.572490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
268 Rau M, Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.Expert Rev Clin Pharmacol. 2021;14:333-340. [PMID: 33535836 DOI: 10.1080/17512433.2021.1884068] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
269 Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol 2017;23:311-7. [PMID: 29205182 DOI: 10.4103/sjg.SJG_161_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
270 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
271 Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, Jebb SA, Aveyard P. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;. [PMID: 31260026 DOI: 10.1001/jamainternmed.2019.2248] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 34.5] [Reference Citation Analysis]
272 Negi CK, Khan S, Dirven H, Bajard L, Bláha L. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:4282. [PMID: 33924165 DOI: 10.3390/ijms22084282] [Reference Citation Analysis]
273 Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, Elsaid MI. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021;161:171-184.e10. [PMID: 33744305 DOI: 10.1053/j.gastro.2021.03.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
274 Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res 2018;112:73-80. [PMID: 30097139 DOI: 10.1016/j.jpsychores.2018.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
275 Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-sun Wong V, Romero-gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2019;17:2552-2560.e10. [DOI: 10.1016/j.cgh.2019.02.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
276 Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-gomez M, Mendez-sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. [DOI: 10.1016/j.cgh.2018.11.033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 22.0] [Reference Citation Analysis]
277 Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology 2018;68:2230-8. [PMID: 29774589 DOI: 10.1002/hep.30094] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
278 Fu S, Yu M, Tan Y, Liu D. Role of histone deacetylase on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:353-61. [PMID: 33213187 DOI: 10.1080/17474124.2021.1854089] [Reference Citation Analysis]
279 Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol 2018;17:11-3. [PMID: 29311407 DOI: 10.5604/01.3001.0010.7530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Bush H, Golabi P, Otgonsuren M, Rafiq N, Venkatesan C, Younossi ZM. Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. J Clin Gastroenterol 2019;53:58-64. [PMID: 29608451 DOI: 10.1097/MCG.0000000000001026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
281 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 228] [Article Influence: 63.0] [Reference Citation Analysis]
282 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
283 Patton H, Burchette R, Tovar S, Pio J, Shi J, Nyberg LM. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT. BMC Gastroenterol 2020;20:362. [PMID: 33129272 DOI: 10.1186/s12876-020-01492-9] [Reference Citation Analysis]
284 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
285 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
286 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Koyama M, Ohnishi H, Numata K, Hisasue T, Hanawa N, Moniwa N, Tsuchihashi K, Miura T. High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. Sci Rep 2021;11:12830. [PMID: 34145341 DOI: 10.1038/s41598-021-92292-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ 2021;22:505-18. [PMID: 33751289 DOI: 10.1007/s10198-020-01256-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
289 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
290 Li Z, Ye CY, Wang L, Li JM, Yang L. Association of Genetic and Environmental Factors with Non-Alcoholic Fatty Liver Disease in a Chinese Han Population. Int J Environ Res Public Health 2020;17:E5217. [PMID: 32698306 DOI: 10.3390/ijerph17145217] [Reference Citation Analysis]
291 Ritz T, Krenkel O, Tacke F. Dynamic plasticity of macrophage functions in diseased liver. Cell Immunol 2018;330:175-82. [PMID: 29454647 DOI: 10.1016/j.cellimm.2017.12.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
292 Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie 2017;136:65-74. [PMID: 27916647 DOI: 10.1016/j.biochi.2016.11.009] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 20.6] [Reference Citation Analysis]
293 Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun 2021. [PMID: 34558835 DOI: 10.1002/hep4.1696] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Easter JA, Tian Y, Burrell RC, Hong Y, Bonacorsi SJ Jr. Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin. J Labelled Comp Radiopharm 2021. [PMID: 34386991 DOI: 10.1002/jlcr.3940] [Reference Citation Analysis]
295 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
296 Thiagarajan P, Chalmers J, Ban L, Grindlay D, Aithal GP. L-carnitine supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World J Meta-Anal 2020; 8(1): 4-14 [DOI: 10.13105/wjma.v8.i1.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
297 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
298 Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. [PMID: 29137912 DOI: 10.1016/j.metabol.2017.11.003] [Cited by in Crossref: 131] [Cited by in F6Publishing: 118] [Article Influence: 32.8] [Reference Citation Analysis]
299 Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol 2019; 25(11): 1307-1326 [PMID: 30918425 DOI: 10.3748/wjg.v25.i11.1307] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 52] [Article Influence: 31.5] [Reference Citation Analysis]
300 Zakeri N, Tsochatzis EA. Steatosis affects the sensitivity but not the specificity of non-invasive fibrosis tests in non-alcoholic fatty liver disease - implications for screening strategies. Liver Int 2018;38:224-6. [DOI: 10.1111/liv.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
301 Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E298. [PMID: 30642126 DOI: 10.3390/ijms20020298] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
302 Lodhi M, Amin J, Eswaran S. Role of alcohol in nonalcoholic steatohepatitis: Rush university (Con) patients with nonalcoholic steatohepatitis should be abstinent from alcohol use. Clin Liver Dis (Hoboken) 2018;11:39-42. [PMID: 30992785 DOI: 10.1002/cld.669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Kleinstein SE, Rein M, Abdelmalek MF, Guy CD, Goldstein DB, Mae Diehl A, Moylan CA. Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD. Hepatol Commun 2018;2:1021-9. [PMID: 30202817 DOI: 10.1002/hep4.1227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Kostallari E, Valainathan S, Biquard L, Shah VH, Rautou PE. Role of extracellular vesicles in liver diseases and their therapeutic potential. Adv Drug Deliv Rev 2021;175:113816. [PMID: 34087329 DOI: 10.1016/j.addr.2021.05.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Ai L, Luo W, Yuan P, Liu L, Zhou Y. Liver macrophages mediate effects of downhill running and caloric restriction on nonalcoholic fatty liver disease of high fat diet-fed mice. Life Sci 2020;256:117978. [PMID: 32553927 DOI: 10.1016/j.lfs.2020.117978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
306 Younossi ZM, Henry L. Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time? Gastroenterology 2020;158:40-2. [PMID: 31743732 DOI: 10.1053/j.gastro.2019.11.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
307 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 O'Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, Morgan G, Hebditch V, Jönsson B, Mabhala M, Reic T, Van Thiel I, Ratziu V, Romero-Gomez M, Bugianesi E, Schattenberg JM, Anstee QM. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep 2020;2:100142. [PMID: 32775976 DOI: 10.1016/j.jhepr.2020.100142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
309 Xue Y, Liu H, Yang XX, Pang L, Liu J, Ng KTP, Yeung OWH, Lam YF, Zhang WY, Lo CM, Man K. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation 2021;105:550-60. [PMID: 32890136 DOI: 10.1097/TP.0000000000003437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Xu M, Ge C, Qin Y, Gu T, Lv J, Wang S, Ma Y, Lou D, Li Q, Hu L, Nie X, Wang M, Huang P, Tan J. Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention. Food Funct 2019;10:1302-16. [DOI: 10.1039/c8fo01615a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 8.5] [Reference Citation Analysis]
311 Younossi ZM. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. Clin Gastroenterol Hepatol 2017;15:1144-7. [PMID: 28549675 DOI: 10.1016/j.cgh.2017.05.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
312 Cichocki JA, Furuya S, Luo YS, Iwata Y, Konganti K, Chiu WA, Threadgill DW, Pogribny IP, Rusyn I. Nonalcoholic Fatty Liver Disease Is a Susceptibility Factor for Perchloroethylene-Induced Liver Effects in Mice. Toxicol Sci 2017;159:102-13. [PMID: 28903486 DOI: 10.1093/toxsci/kfx120] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
313 Hirode G, Vittinghoff E, Wong RJ. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States. J Clin Gastroenterol. 2019;53:765-771. [PMID: 31135632 DOI: 10.1097/mcg.0000000000001229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
314 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, Mccormack L, Gadano A, Boin ISF, García P, Silva M. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clinics and Research in Hepatology and Gastroenterology 2018;42:443-52. [DOI: 10.1016/j.clinre.2018.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
315 Chiou YL, Chyau CC, Li TJ, Kuo CF, Kang YY, Chen CC, Ko WS. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Coll Nutr 2021;40:349-57. [PMID: 32657670 DOI: 10.1080/07315724.2020.1779850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
316 Ando W, Yokomori H, Tsutsui N, Yamanouchi E, Suzuki Y, Oda M, Inagaki Y, Otori K, Okazaki I. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin Mol Hepatol. 2018;24:61-76. [PMID: 29151327 DOI: 10.3350/cmh.2017.0030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
317 Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci 2020;21:E8362. [PMID: 33171811 DOI: 10.3390/ijms21218362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
318 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
319 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
320 Vilar-gomez E, Calzadilla-bertot L, Wai-sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-fabian L, Alvarez-quiñones Sanz M, Conde-martin AF, De Boer B, Mcleod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-gomez M. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 2018;155:443-457.e17. [DOI: 10.1053/j.gastro.2018.04.034] [Cited by in Crossref: 235] [Cited by in F6Publishing: 231] [Article Influence: 78.3] [Reference Citation Analysis]
321 Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01131-9. [PMID: 34666156 DOI: 10.1016/j.cgh.2021.10.018] [Reference Citation Analysis]
322 Crawford MS, Mohr AE, Sweazea KL. Novel Organic Mineral Complex Prevents High-Fat Diet-Induced Changes in the Gut and Liver of Male Sprague-Dawley Rats. J Nutr Metab 2020;2020:8846401. [PMID: 33414960 DOI: 10.1155/2020/8846401] [Reference Citation Analysis]
323 Rajan PK, Udoh UA, Sanabria JD, Banerjee M, Smith G, Schade MS, Sanabria J, Sodhi K, Pierre S, Xie Z, Shapiro JI, Sanabria J. The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8894. [PMID: 33255318 DOI: 10.3390/ijms21238894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
324 唐外姣, 周本杰. 肠道菌群失调--非酒精性脂肪肝病治疗新靶点. 世界华人消化杂志 2017; 25(22): 2000-2006 [DOI: 10.11569/wcjd.v25.i22.2000] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
325 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
326 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 39.7] [Reference Citation Analysis]
327 Peng Y, Li JZ, You M, Murr MM. Roux-en-Y gastric bypass improves glucose homeostasis, reduces oxidative stress and inflammation in livers of obese rats and in Kupffer cells via an AMPK-dependent pathway. Surgery 2017;162:59-67. [PMID: 28291540 DOI: 10.1016/j.surg.2017.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
328 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
329 Ferraioli G, Maiocchi L, Raciti MV, Tinelli C, De Silvestri A, Nichetti M, De Cata P, Rondanelli M, Chiovato L, Calliada F, Filice C; on behalf of the Liver Steatosis Study Group. Detection of liver steatosis with a novel ultrasound-based technique: a pilot study using MRI-PDFF as the gold standard. Clin Transl Gastroenterol. 2019;. [PMID: 31609745 DOI: 10.14309/ctg.0000000000000081] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 29.0] [Reference Citation Analysis]
330 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 72.0] [Reference Citation Analysis]
331 Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv Ther 2019;36:1574-94. [PMID: 31065991 DOI: 10.1007/s12325-019-00960-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
332 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 205.0] [Reference Citation Analysis]
334 Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opin Drug Metab Toxicol 2017;13:625-40. [PMID: 28359183 DOI: 10.1080/17425255.2017.1314461] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
335 Ritz T, Tacke F. The Janus-like Face of IL-4Rα in Macrophages during Liver Fibrosis. EBioMedicine 2018;29:7-8. [PMID: 29428523 DOI: 10.1016/j.ebiom.2018.02.004] [Reference Citation Analysis]
336 Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, Targher G. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid 2018;28:1270-84. [DOI: 10.1089/thy.2018.0257] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 13.7] [Reference Citation Analysis]
337 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
338 Słomko J, Zalewska M, Niemiro W, Kujawski S, Słupski M, Januszko-Giergielewicz B, Zawadka-Kunikowska M, Newton J, Hodges L, Kubica J, Zalewski P. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:1659. [PMID: 33924482 DOI: 10.3390/jcm10081659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
339 Zhou B, Yang H, Xu W, Wang K, Guo P, Ai Y. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A systematic review and meta‐analysis of observational studies. Helicobacter 2019;24:e12576. [DOI: 10.1111/hel.12576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
340 Aggarwal M, Rozenbaum D, Bansal A, Garg R, Bansal P, McCullough A. Development of machine learning model to detect fibrotic non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00386-8. [PMID: 34400107 DOI: 10.1016/j.dld.2021.07.016] [Reference Citation Analysis]
341 Altaf B, Rehman A, Jawed S, Raouf A. Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. Pak J Med Sci 2020;36:387-90. [PMID: 32292439 DOI: 10.12669/pjms.36.3.1674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Cotter TG, Dong L, Holmen J, Gilroy R, Krong J, Charlton M. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol 2020;55:722-30. [DOI: 10.1007/s00535-020-01684-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
343 Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, Machann J, Hierholzer J, Roden M, Pfeiffer AFH. Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men-A Randomized Controlled Trial. Mol Nutr Food Res 2020;64:e2000419. [PMID: 32920973 DOI: 10.1002/mnfr.202000419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
344 Lapumnuaypol K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:854-860. [PMID: 29697458 DOI: 10.1097/meg.0000000000001144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
345 Raichur S. Ceramide Synthases Are Attractive Drug Targets for Treating Metabolic Diseases. Front Endocrinol (Lausanne). 2020;11:483. [PMID: 32849276 DOI: 10.3389/fendo.2020.00483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
346 Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019;70:1913-1927. [PMID: 30993748 DOI: 10.1002/hep.30664] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 37.5] [Reference Citation Analysis]
347 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34:1291-1326. [PMID: 28526997 DOI: 10.1007/s12325-017-0556-1] [Cited by in Crossref: 197] [Cited by in F6Publishing: 188] [Article Influence: 49.3] [Reference Citation Analysis]
348 Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Transl Gastroenterol Hepatol 2021;6:5. [PMID: 33409399 DOI: 10.21037/tgh.2020.01.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 de Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2020;105:dgaa575. [PMID: 32827432 DOI: 10.1210/clinem/dgaa575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
350 Cichocki JA, Furuya S, Konganti K, Luo YS, McDonald TJ, Iwata Y, Chiu WA, Threadgill DW, Pogribny IP, Rusyn I. Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice. J Pharmacol Exp Ther 2017;361:17-28. [PMID: 28148637 DOI: 10.1124/jpet.116.238790] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
351 Gnocchi D, Custodero C, Sabbà C, Mazzocca A. Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. J Mol Med (Berl) 2019;97:741-59. [PMID: 30953079 DOI: 10.1007/s00109-019-01780-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
352 Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou P. Non-Alcoholic Fatty Liver Disease and Vascular Disease. CVP 2020;19:269-79. [DOI: 10.2174/1570161118666200318103001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
353 Chuah K, Chan W. Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Aliment Pharmacol Ther 2020;51:1429-30. [DOI: 10.1111/apt.15700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
354 Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K, Nakajima A. Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. Hepatol Res 2020;50:955-65. [PMID: 32455496 DOI: 10.1111/hepr.13528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
355 Jimenez LS, Mendonça Chaim FH, Mendonça Chaim FD, Utrini MP, Gestic MA, Chaim EA, Cazzo E. Impact of Weight Regain on the Evolution of Non-alcoholic Fatty Liver Disease After Roux-en-Y Gastric Bypass: a 3-Year Follow-up. Obes Surg 2018;28:3131-5. [PMID: 29725976 DOI: 10.1007/s11695-018-3286-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
356 Fernando H, Bhopale KK, Kondraganti SS, Kaphalia BS, Ansari GAS. Alcohol-Induced Hepatic Steatosis: A Comparative Study to Identify Possible Indicator(s) of Alcoholic Fatty Liver Disease. J Drug Alcohol Res 2018;7:236040. [PMID: 31032137 DOI: 10.4303/jdar/236040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
357 Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) 2017;4:E48. [PMID: 28598410 DOI: 10.3390/children4060048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
358 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
359 Zou ZY, Shen B, Fan JG. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25:1764-1772. [PMID: 30918952 DOI: 10.1093/ibd/izz043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
360 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 707.3] [Reference Citation Analysis]
361 Kutzler HL, Peters J, O’sullivan DM, Williamson A, Cheema F, Ebcioglu Z, Einstein M, Rochon C, Ye X, Sheiner P, Singh JU, Sotil EU, Swales C, Serrano OK. Disparities in End-Organ Care for Hispanic Patients with Kidney and Liver Disease: Implications for Access to Transplantation. Curr Surg Rep 2020;8. [DOI: 10.1007/s40137-020-00248-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
363 Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
364 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 150.5] [Reference Citation Analysis]
365 Bayrak M. Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors. Aging Male 2020;23:1275-82. [PMID: 32396414 DOI: 10.1080/13685538.2020.1763293] [Reference Citation Analysis]
366 Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl) 2020;133:2271-3. [PMID: 32701591 DOI: 10.1097/CM9.0000000000000981] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
367 Wu B, Xiao Z, Zhang W, Chen H, Liu H, Pan J, Cai X, Liang G, Zhou B, Shan X, Zhang Y. A novel resveratrol-curcumin hybrid, a19, attenuates high fat diet-induced nonalcoholic fatty liver disease. Biomedicine & Pharmacotherapy 2019;110:951-60. [DOI: 10.1016/j.biopha.2018.11.088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
368 Mann JP, Tang GY, Nobili V, Armstrong MJ. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clinical Gastroenterology and Hepatology 2019;17:1457-1476.e7. [DOI: 10.1016/j.cgh.2018.05.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
369 Pham TX, Lee Y, Bae M, Hu S, Kang H, Kim MB, Park YK, Lee JY. Spirulina supplementation in a mouse model of diet-induced liver fibrosis reduced the pro-inflammatory response of splenocytes. Br J Nutr 2019;121:748-55. [PMID: 30806344 DOI: 10.1017/S0007114519000126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
370 Purcell Y, Copin P, Paradis V, Vilgrain V, Ronot M. Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. Br J Radiol 2019;92:20180701. [PMID: 30604641 DOI: 10.1259/bjr.20180701] [Reference Citation Analysis]
371 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
372 Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma: Does the Background Liver With or Without Cirrhosis Matter? Am J Clin Pathol 2021:aqab125. [PMID: 34542582 DOI: 10.1093/ajcp/aqab125] [Reference Citation Analysis]
373 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
374 C. Gordon S, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol 2020;115:562-74. [DOI: 10.14309/ajg.0000000000000484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
375 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
376 Mann JP, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B, Chandran S, More R, Newsome PN, Potluri R. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS One. 2020;15:e0241357. [PMID: 33108366 DOI: 10.1371/journal.pone.0241357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421-8. [PMID: 29404470 DOI: 10.1002/hep4.1054] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
378 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
379 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
380 Brattain LJ, Telfer BA, Dhyani M, Grajo JR, Samir AE. Objective Liver Fibrosis Estimation from Shear Wave Elastography.Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:1-5. [PMID: 30440285 DOI: 10.1109/EMBC.2018.8513011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
381 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 111] [Article Influence: 51.0] [Reference Citation Analysis]
382 Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath. 2018;22:841-851. [PMID: 29335916 DOI: 10.1007/s11325-018-1625-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
383 Amanatidou AI, Dedoussis GV. Construction and analysis of protein-protein interaction network of non-alcoholic fatty liver disease. Comput Biol Med 2021;131:104243. [PMID: 33550014 DOI: 10.1016/j.compbiomed.2021.104243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
384 Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Gunn PJ, Pramfalk C, Millar V, Cornfield T, Hutchinson M, Johnson EM, Nagarajan SR, Troncoso-Rey P, Mithen RF, Pinnick KE, Traka MH, Green CJ, Hodson L. Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis. Physiol Rep 2020;8:e14482. [PMID: 32643289 DOI: 10.14814/phy2.14482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Nagasaki A, Sakamoto S, Arai T, Kato M, Ishida E, Furusho H, Fujii M, Takata T, Miyauchi M. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH. J Clin Periodontol 2021. [PMID: 34250613 DOI: 10.1111/jcpe.13523] [Reference Citation Analysis]
387 Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41:1227-42. [PMID: 33590598 DOI: 10.1111/liv.14825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
388 Ye L, Cao Z, Lai X, Shi Y, Zhou N. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. J Nutr 2020;150:672-84. [PMID: 31858105 DOI: 10.1093/jn/nxz303] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
389 Heredia NI, Thrift AP, Balakrishnan M. Perceived Barriers to Weight Loss among Hispanic Patients with Non-alcoholic Fatty Liver Disease. Hisp Health Care Int 2021;:15404153211043885. [PMID: 34658280 DOI: 10.1177/15404153211043885] [Reference Citation Analysis]
390 Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol 2021;19:136-145.e6. [PMID: 32389886 DOI: 10.1016/j.cgh.2020.04.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
391 Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
392 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
393 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 37.0] [Reference Citation Analysis]
394 Shu Z, Liu W, Wu H, Xiao M, Wu D, Cao T, Ren M, Tao J, Zhang C, He T, Li X, Zhang R, Zhou X. Symptom-based network classification identifies distinct clinical subgroups of liver diseases with common molecular pathways. Comput Methods Programs Biomed 2019;174:41-50. [PMID: 29502851 DOI: 10.1016/j.cmpb.2018.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
395 Li C, Ye J, Prince M, Peng Y, Dou W, Shang S, Wu J, Luo X. Comparing mono-exponential, bi-exponential, and stretched-exponential diffusion-weighted MR imaging for stratifying non-alcoholic fatty liver disease in a rabbit model. Eur Radiol 2020;30:6022-32. [PMID: 32591883 DOI: 10.1007/s00330-020-07005-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
396 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 178] [Article Influence: 47.5] [Reference Citation Analysis]
397 Orang Z, Mohsenpour MA, Mozaffari-khosravi H. Effect of Omega-3 fatty acid supplementation on inflammatory markers and insulin resistance indices in patient with type 2 diabetes and nonalcoholic fatty liver: A randomized double-blind clinical trial. Obesity Medicine 2020;19:100278. [DOI: 10.1016/j.obmed.2020.100278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
398 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
399 Fang X, Wang H, Ye T, Fu X, Tan X, Zeng Y, Fan J, Xu Y. Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis 2021;20:96. [PMID: 34461919 DOI: 10.1186/s12944-021-01518-5] [Reference Citation Analysis]
400 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
401 Danford CJ, Sanchez JE, Corey KE. Managing the Burden of Non-NASH NAFLD. Curr Hepatol Rep 2017;16:326-34. [PMID: 29503789 DOI: 10.1007/s11901-017-0371-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
402 Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152:1656-1670. [PMID: 28192107 DOI: 10.1053/j.gastro.2016.12.052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 20.3] [Reference Citation Analysis]
403 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Boutot ME, Whitcomb BW, Abdelouahab N, Baccarelli AA, Boivin A, Caku A, Gillet V, Martinez G, Pasquier JC, Zhu J, Takser L, St-Cyr L, Suvorov A. In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels. Metabolites 2021;11:657. [PMID: 34677372 DOI: 10.3390/metabo11100657] [Reference Citation Analysis]
405 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
406 Colak Y, Hasan B, Erkalma B, Tandon K, Zervos X, Menzo EL, Erim T. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. Clin Res Hepatol Gastroenterol 2021;45:101710. [PMID: 33930586 DOI: 10.1016/j.clinre.2021.101710] [Reference Citation Analysis]
407 Canbay A, Kachru N, Haas JS, Sowa J, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;52:1185-94. [DOI: 10.1111/apt.16016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
408 Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-gómez M, Anstee QM, Schattenberg JM. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology 2019;17:2085-2092.e1. [DOI: 10.1016/j.cgh.2018.12.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
409 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
410 Golabi P, Bush H, Younossi ZM. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 2017;21:739-53. [PMID: 28987260 DOI: 10.1016/j.cld.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
411 Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore) 2018;97:e0214. [PMID: 29595666 DOI: 10.1097/MD.0000000000010214] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 20.3] [Reference Citation Analysis]
412 Chen YS, Chen D, Shen C, Chen M, Jin CH, Xu CF, Yu CH, Li YM. A novel model for predicting fatty liver disease by means of an artificial neural network. Gastroenterol Rep (Oxf) 2021;9:31-7. [PMID: 33747524 DOI: 10.1093/gastro/goaa035] [Reference Citation Analysis]
413 Xi Y, Li H. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed Pharmacother 2020;121:109609. [PMID: 31731192 DOI: 10.1016/j.biopha.2019.109609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
414 Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Jimenez MA, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine 2021;73:103661. [PMID: 34740106 DOI: 10.1016/j.ebiom.2021.103661] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Zheng KI, Liu WY, Pan XY, Ma HL, Zhu PW, Wu XX, Targher G, Byrne C, Wang XD, Chen YP, Lu F, Zheng MH. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Res Care 2020;8:e001174. [PMID: 32139603 DOI: 10.1136/bmjdrc-2020-001174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
416 Adams LC, Lübbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. PLoS One 2018;13:e0206450. [PMID: 30427909 DOI: 10.1371/journal.pone.0206450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
417 Dibba P, Li AA, Cholankeril G, Ali Khan M, Kim D, Ahmed A. Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary. Nutr Metab Insights 2019;12:1178638819847480. [PMID: 31308686 DOI: 10.1177/1178638819847480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
418 Wong RJ, Singal AK. Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019. JAMA Netw Open 2020;3:e1920294. [PMID: 32022875 DOI: 10.1001/jamanetworkopen.2019.20294] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 28.0] [Reference Citation Analysis]
419 Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. Diabetes 2018;67:2485-93. [PMID: 30459251 DOI: 10.2337/dbi18-0024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 21.0] [Reference Citation Analysis]
420 Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11:92-94. [PMID: 30992797 DOI: 10.1002/cld.710] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
421 Shin HS. Association between periodontal status and non-alcoholic fatty liver disease in a Korean adult population: A nationwide cross-sectional study. J Periodontol 2020;91:524-32. [PMID: 31484207 DOI: 10.1002/JPER.19-0291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
422 Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol 2020. [PMID: 32185502 DOI: 10.1007/164_2020_352] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999-2014.e1. [DOI: 10.1053/j.gastro.2019.11.312] [Cited by in Crossref: 428] [Cited by in F6Publishing: 423] [Article Influence: 428.0] [Reference Citation Analysis]
424 Fukui N, Golabi P, Otgonsuren M, Mishra A, Venkatesan C, Younossi ZM. Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States. Am J Gastroenterol 2017;112:1700-8. [PMID: 29016566 DOI: 10.1038/ajg.2017.290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
425 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
426 Lefebvre T, Hébert M, Bilodeau L, Sebastiani G, Cerny M, Olivié D, Gao ZH, Sylvestre MP, Cloutier G, Nguyen BN, Gilbert G, Tang A. Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. Eur Radiol 2021;31:1347-58. [PMID: 32876833 DOI: 10.1007/s00330-020-07203-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
427 Rowe IA, Parker R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. Nat Rev Gastroenterol Hepatol 2019;16:449-50. [PMID: 31197261 DOI: 10.1038/s41575-019-0168-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
428 Brunt EM. Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist. J Hepatol 2020;73:1310-2. [PMID: 32890594 DOI: 10.1016/j.jhep.2020.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
429 Cichocki JA, Luo YS, Furuya S, Venkatratnam A, Konganti K, Chiu WA, Threadgill DW, Pogribny IP, Rusyn I. Modulation of Tetrachloroethylene-Associated Kidney Effects by Nonalcoholic Fatty Liver or Steatohepatitis in Male C57BL/6J Mice. Toxicol Sci 2019;167:126-37. [PMID: 30202895 DOI: 10.1093/toxsci/kfy223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
430 Cai J, Zhang XJ, Li H. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. Trends Endocrinol Metab 2018;29:712-22. [PMID: 30131212 DOI: 10.1016/j.tem.2018.08.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
431 Song M, Xia L, Liu Q, Sun M, Wang F, Yang C. Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved. Adv Exp Med Biol 2018;1088:413-33. [PMID: 30390263 DOI: 10.1007/978-981-13-1435-3_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
432 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
433 Dhaliwal HS, Singh R, Abraham AM, Sharma R, Goyal NK, Soloman R, Bansal P, Goyal A. Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33409801 DOI: 10.1007/s10620-020-06794-2] [Reference Citation Analysis]
434 Du C, Shen L, Ma Z, Du J, Jin S. Bioinformatic Analysis of Crosstalk Between circRNA, miRNA, and Target Gene Network in NAFLD. Front Genet 2021;12:671523. [PMID: 33995497 DOI: 10.3389/fgene.2021.671523] [Reference Citation Analysis]
435 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
436 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39:924-32. [PMID: 30253043 DOI: 10.1111/liv.13974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
437 Lugari S, Mantovani A, Nascimbeni F, Lonardo A. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30367792 DOI: 10.1515/hmbci-2018-0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
438 Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, Hur K, Han MH, Lee WK. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. Ann Lab Med 2021;41:302-9. [PMID: 33303715 DOI: 10.3343/alm.2021.41.3.302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
439 Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM, Negro F. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52. [DOI: 10.1111/liv.13992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
440 Geier A, Rinella ME, Balp MM, McKenna SJ, Brass CA, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Ratziu V. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021;19:1020-1029.e7. [PMID: 32634622 DOI: 10.1016/j.cgh.2020.06.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
441 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
442 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. [PMID: 33283415 DOI: 10.1111/liv.14749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
443 Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425-439. [PMID: 29713021 DOI: 10.1038/s41575-018-0010-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 42.5] [Reference Citation Analysis]
444 Méndez-Sánchez N, Zamarripa-Dorsey F, Panduro A, Purón-González E, Coronado-Alejandro EU, Cortez-Hernández CA, Higuera de la Tijera F, Pérez-Hernández JL, Cerda-Reyes E, Rodríguez-Hernández H, Cruz-Ramón VC, Ramírez-Pérez OL, Aguilar-Olivos NE, Rodríguez-Martínez OF, Cabrera-Palma S, Cabrera-Álvarez G. Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions. World J Clin Cases 2018; 6(15): 922-930 [PMID: 30568947 DOI: 10.12998/wjcc.v6.i15.922] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
445 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open 2020;10:e036663. [PMID: 32747349 DOI: 10.1136/bmjopen-2019-036663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
447 Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020;98:106175. [PMID: 33045403 DOI: 10.1016/j.cct.2020.106175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
448 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
449 Ayyash A, Holloway AC. Fluoxetine-induced hepatic lipid accumulation is linked to elevated serotonin production. Can J Physiol Pharmacol 2021;99:983-8. [PMID: 33517848 DOI: 10.1139/cjpp-2020-0721] [Reference Citation Analysis]
450 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
451 Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, Diemen VV, Cerski CTS, Schaan BD. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract 2021;15:461-5. [PMID: 34511367 DOI: 10.1016/j.orcp.2021.09.002] [Reference Citation Analysis]